|
1
|
Zaha DC: Significance of
immunohistochemistry in breast cancer. World J Clin Oncol.
5:382–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Su Y, Diez PJ Gutiérrez, Pereira J
Santucci, Russo IH and Russo J: In situ methods for identifying the
stem cell of the normal and cancerous breastTechniques and
Methodological Approaches in Breast Cancer Research. Russo J and
Russo IH: Springer; New-York: pp. 151–182. 2014, doi:
10.1007/978-1-4939-0718-2_6. View Article : Google Scholar
|
|
3
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
5
|
Wolff AC, Hammond MEH, Schwartz JN,
Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna
WM, Langer A, et al: American Society of Clinical Oncology/College
of American Pathologists: American Society of Clinical
Oncology/College of American Pathologists guideline recommendations
for human epidermal growth factor receptor 2 testing in breast
cancer. Arch Pathol Lab Med. 131:18–43. 2007.PubMed/NCBI
|
|
6
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ooka M, Sakita I, Fujiwara Y, Tamaki Y,
Yamamoto H, Aihara T, Miyazaki M, Kadota M, Masuda N, Sugita Y, et
al: Selection of mRNA markers for detection of lymph node
micrometastases in breast cancer patients. Oncol Rep. 7:561–566.
2000.PubMed/NCBI
|
|
8
|
Zhu L, Loo WT, Cheng CW and Chow LW:
Possible predictive markers related to micro-metastasis in breast
cancer patients. Oncol Rep. 15:1217–1223. 2006.PubMed/NCBI
|
|
9
|
Jones C, Mackay A, Grigoriadis A, Cossu A,
Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, et
al: Expression profiling of purified normal human luminal and
myoepithelial breast cells: Identification of novel prognostic
markers for breast cancer. Cancer Res. 64:3037–3045. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kristiansen G, Winzer KJ, Mayordomo E,
Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P,
Guski H, et al: CD24 expression is a new prognostic marker in
breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
|
|
11
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang M, Behbod F, Atkinson RL, Landis MD,
Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green
JE, et al: Identification of tumor-initiating cells in a p53-null
mouse model of breast cancer. Cancer Res. 68:4674–4682. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sleeman KE, Kendrick H, Ashworth A, Isacke
CM and Smalley MJ: CD24 staining of mouse mammary gland cells
defines luminal epithelial, myoepithelial/basal and non-epithelial
cells. Breast Cancer Res. 8:R72006. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Perrone G, Gaeta LM, Zagami M, Nasorri F,
Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L,
Tonini G, et al: In situ identification of
CD44+/CD24− cancer cells in primary human
breast carcinomas. PLoS One. 7:e431102012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lo PK, Kanojia D, Liu X, Singh UP, Berger
FG, Wang Q and Chen H: CD49f and CD61 identify Her2/neu-induced
mammary tumor-initiating cells that are potentially derived from
luminal progenitors and maintained by the integrin-TGFβ signaling.
Oncogene. 31:2614–2626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vaillant F, Asselin-Labat ML, Shackleton
M, Forrest NC, Lindeman GJ and Visvader JE: The mammary progenitor
marker CD61/beta3 integrin identifies cancer stem cells in mouse
models of mammary tumorigenesis. Cancer Res. 68:7711–7717. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clarke CL, Sandle J, Parry SC, Reis-Filho
JS, O'Hare MJ and Lakhani SR: Cytokeratin 5/6 in normal human
breast: Lack of evidence for a stem cell phenotype. J Pathol.
204:147–152. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Böcker W, Hungermann D, Weigel S, Tio J
and Decker T: Immunohistochemistry in breast pathology:
Differential diagnosis of epithelial breast lesions. Pathologe.
30:13–19. 2009.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aguiar FN, Mendes HN, Cirqueira CS, Bacchi
CE and Carvalho FM: Basal cytokeratin as a potential marker of low
risk of invasion in ductal carcinoma in situ. Clinics (São Paulo).
68:638–643. 2013. View Article : Google Scholar
|
|
20
|
Cimino A, Halushka M, Illei P, Wu X,
Sukumar S and Argani P: Epithelial cell adhesion molecule (EpCAM)
is overexpressed in breast cancer metastases. Breast Cancer Res
Treat. 123:701–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naylor MJ, Li N, Cheung J, Lowe ET,
Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schüetz
G, et al: Ablation of beta1 integrin in mammary epithelium reveals
a key role for integrin in glandular morphogenesis and
differentiation. J Cell Biol. 171:717–728. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
dos Santos PB, Zanetti JS, Ribeiro-Silva A
and Beltrão EI: Beta 1 integrin predicts survival in breast cancer:
A clinicopathological and immunohistochemical study. Diagn Pathol.
7:1042012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yao ES, Zhang H, Chen YY, Lee B, Chew K,
Moore D and Park C: Increased beta1 integrin is associated with
decreased survival in invasive breast cancer. Cancer Res.
67:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gonzalez MA, Pinder SE, Wencyk PM, Bell
JA, Elston CW, Nicholson RI, Robertson JF, Blamey RW and Ellis IO:
An immunohistochemical examination of the expression of E-cadherin,
alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in
invasive breast cancer. J Pathol. 187:523–529. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ivaska J, Pallari HM, Nevo J and Eriksson
JE: Novel functions of vimentin in cell adhesion, migration, and
signaling. Exp Cell Res. 313:2050–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Domagala W, Lasota J, Bartkowiak J, Weber
K and Osborn M: Vimentin is preferentially expressed in human
breast carcinomas with low estrogen receptor and high Ki-67 growth
fraction. Am J Pathol. 136:219–227. 1990.PubMed/NCBI
|
|
28
|
Korsching E, Packeisen J, Liedtke C,
Hungermann D, Wülfing P, van Diest PJ, Brandt B, Boecker W and
Buerger H: The origin of vimentin expression in invasive breast
cancer: Epithelial-mesenchymal transition, myoepithelial
histogenesis or histogenesis from progenitor cells with bilinear
differentiation potential? J Pathol. 206:451–457. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hemalatha A, Suresh TN and Kumar ML:
Expression of vimentin in breast carcinoma, its correlation with
Ki67 and other histopathological parameters. Indian J Cancer.
50:189–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kusinska RU, Kordek R, Pluciennik E,
Bednarek AK, Piekarski JH and Potemski P: Does vimentin help to
delineate the so-called ‘basal type breast cancer’? J Exp Clin
Cancer Res. 28:1182009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th edition
of the AJCC Cancer Staging Manual. Surg Clin North Am. 83:803–19.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Singletary SE and Connolly JL: Breast
cancer staging: working with the sixth edition of the AJCC Cancer
Staging Manual. CA Cancer J Clin. 56:37–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park SY, Lee HE, Li H, Shipitsin M, Gelman
R and Polyak K: Heterogeneity for stem cell-related markers
according to tumor subtype and histologic stage in breast cancer.
Clin Cancer Res. 16:876–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hwang-Verslues WW, Kuo WH, Chang PH, Pan
CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, et al:
Multiple lineages of human breast cancer stem/progenitor cells
identified by profiling with stem cell markers. PLoS One.
4:e83772009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lehmann C, Jobs G, Thomas M, Burtscher H
and Kubbies M: Established breast cancer stem cell markers do not
correlate with in vivo tumorigenicity of tumor-initiating
cells. Int J Oncol. 41:1932–1942. 2012.PubMed/NCBI
|
|
37
|
Shackleton M, Vaillant F, Simpson KJ,
Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ and
Visvader JE: Generation of a functional mammary gland from a single
stem cell. Nature. 439:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fillmore CM and Kuperwasser C: Human
breast cancer cell lines contain stem-like cells that self-renew,
give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liao MJ, Zhang CC, Zhou B, Zimonjic DB,
Mani SA, Kaba M, Gifford A, Reinhardt F, Popescu NC, Guo W, et al:
Enrichment of a population of mammary gland cells that form
mammospheres and have in vivo repopulating activity. Cancer Res.
67:8131–8138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stingl J, Eirew P, Ricketson I, Shackleton
M, Vaillant F, Choi D, Li HI and Eaves CJ: Purification and unique
properties of mammary epithelial stem cells. Nature. 439:993–997.
2006.PubMed/NCBI
|
|
41
|
Cariati M, Naderi A, Brown JP, Smalley MJ,
Pinder SE, Caldas C and Purushotham AD: Alpha-6 integrin is
necessary for the tumourigenicity of a stem cell-like subpopulation
within the MCF7 breast cancer cell line. Int J Cancer. 122:298–304.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pommier SJ, Hernandez A, Han E, Massimino
K, Muller P, Diggs B, Chamberlain E, Murphy J, Hansen J, Naik A, et
al: Fresh surgical specimens yield breast stem/progenitor cells and
reveal their oncogenic abnormalities. Ann Surg Oncol. 19:527–535.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dobson AJ and Barnett AG: An Introduction
to Generalized Linear ModelsThird Edition. Chapman and Hall/CRC.
Taylor & Francis Group; 2008
|
|
44
|
Greene WH: Econometric Analysis.
MacMillan; 1993
|
|
45
|
Aitchison J and Silvey SD: The
generalization of probit analysis to the case of multiple
responses. Biometrika. 44:131–140. 1957. View Article : Google Scholar
|
|
46
|
McCullagh P and Nelder JA: Generalized
Linear Models. Chapman & Hall; New York: 1990
|
|
47
|
Long JS: Regression Models for Categorical
and Limited Dependent Variables. 7. Sage Publications; 1997
|
